Global Niacin and Niacinamide Market Trends and Insights
Expanding Food and Feed Fortification Programs
Government-supported fortification programs provide the niacin and niacinamide market with demand that is tied to nutrition policy and monitored procurement. Ethiopia’s food fortification plan reached full implementation on August 31, 2024, and requires niacin fortification of wheat flour under Ethiopian Standard 309. Wider coordination among West African countries can support longer supply agreements instead of irregular spot purchases. Such arrangements give regional distributors clearer volume expectations and give producers more stable sales channels, because regular compliance purchasing is easier to plan than occasional imports that depend on changing local inventory levels. EU rules also govern additives used in animal nutrition, supporting demand for certified niacin in livestock premixes. China’s tighter feed registration requirements also raise the importance of purity and documentation in domestic ingredient sourcing, which can make established producers more attractive when processors must demonstrate that their premix inputs meet defined standards.Rising Preventive Healthcare and Supplement Consumption
Preventive healthcare is broadening the use of niacin and niacinamide beyond narrow therapeutic applications. A 2025 randomized clinical trial reported that niacin reduced lipoprotein(a) by 11.4% and LDL-C by 31.9% among hemodialysis patients. These results sustain interest in pharmaceutical-grade material for high-risk cardiovascular populations. Niacinamide is also under clinical investigation for neuroprotective uses in Alzheimer’s disease and Parkinson’s disease, encouraging manufacturers to consider dedicated high-purity products for older consumers while the clinical work continues. Supplement brands serving older consumers, therefore, need high-purity material and stronger product documentation. The resulting preference for detailed specifications and certificates of analysis differentiates functional-grade supply from commodity material, as brands must be able to explain ingredient quality to customers, regulators, and commercial partners.Niacin Flushing and High-Dose Tolerability Concerns
Niacin flushing remains a material barrier for therapeutic and over-the-counter supplement use. FDA labeling identifies flushing as a prostaglandin-mediated response and reports it in up to 88% of patients using immediate-release formulations. A 2025 study linked an attenuated flushing response with cognitive impairment in late-life depression. This leaves brands with a difficult communication issue because the pathway has both tolerability and research relevance. FDA labeling reported that extended-release products reduced average flushing events from 8.6 to 1.9 in each 4-week period. However, slower pharmacokinetics can reduce peak exposure for certain lipid-management needs, leaving prescribers and patients to balance comfort, dose selection, and the desired clinical response.Other drivers and restraints analyzed in the report include:
- Growth in Pharmaceutical-Grade Vitamin B3 Demand
- Accelerating Niacinamide Use in Dermatological Skincare
- Commodity-Grade Price Competition and Margin Compression
Segment Analysis
Niacinamide held 58.31% of the niacin and niacinamide market share by value in 2025 and is forecast to grow at 8.65% CAGR through 2031. Its use spans cosmetics, nutraceuticals, food fortification, and pharmaceutical products. This broad use base is wider than niacin’s primary exposure to therapeutic and feed channels. Cosmetic brands use niacinamide in premium serums, and pharmaceutical manufacturers qualify it for supplements and topical products. Food processors also select niacinamide for some fortified products because it avoids niacin-related flushing. These combined uses allow the niacin and niacinamide industry to serve several demand streams through one product category. Capacity activity by Lonza, DSM-Firmenich, and Zhejiang NHU during 2024 to 2026 reflected confidence in demand for differentiated grades, where customer qualification processes, batch consistency, and application support can matter as much as available tonnage. The segment’s growth also reflects the value placed on quality assurance and stable product performance by formulators.Niacin continues to have an established role in extended-release dyslipidemia products and metabolic management. It also remains relevant in feed premixes where its cost position is important. Its therapeutic use is constrained by tolerability concerns at high doses. That constraint has limited consumer-health adoption even where pharmacological efficacy is recognized. Standard treatment protocols in regulated markets also use statins and combination lipid therapies. These practices narrow niacin’s growth potential in some therapeutic settings, especially where clinicians have established treatment pathways and patients may be reluctant to accept the tolerability issues associated with higher therapeutic doses. The product is not obsolete, because its core uses remain supported by clinical and feed requirements. Instead, its slower expansion reflects a ceiling in its established channels, because demand is sustained by known uses but does not benefit from the same broad product-development activity visible in niacinamide-based personal care. The niacin and niacinamide market, therefore, retains demand for both products while value growth shifts toward niacinamide.
Synthetic material accounted for 71.24% of the niacin and niacinamide supply share by source in 2025. Established manufacturing economics, reliable purity, and regulatory acceptance support its position in pharmaceutical, food, and feed applications. Conventional production uses catalytic hydration of 3-cyanopyridine through nitrile hydratase or acid-catalyzed hydrolysis. These processes have been improved over many years and can achieve conversion efficiencies above 99%. The scale and consistency of this route remain difficult for newer production methods to match in bulk applications. Synthetic material consequently remains central to high-volume supply contracts. The source segment also benefits from known handling methods and established quality specifications. These characteristics matter to buyers serving several regulated markets because a single material may need to satisfy different documentation, quality, and delivery expectations across pharmaceutical, food, and animal nutrition operations. They also support predictable delivery for large food, feed, and pharmaceutical production runs.
Natural and bio-based materials are forecast to record the fastest source growth at 6.42% CAGR through 2031. Research published in 2025 reported that engineered recombinant E. coli systems achieved 98.6% niacin yield within 40 minutes under optimized conditions. The process can operate under milder conditions and create fewer toxic byproducts than conventional chemical routes, which is relevant to companies that evaluate both product quality and the production practices behind their ingredient choices. Fermentation-derived grades also offer traceability that supports clean-label cosmetics, giving brands a way to align ingredient selection with renewable-feedstock claims and the supply information requested by sustainability-focused customers. Viablife has presented a fermentation-based niacinamide grade for cosmetics, showing the commercial interest in this route. European sustainability requirements and procurement expectations encourage this source shift. Synthetic supply is likely to remain important in bulk feed and pharmaceutical use. Bio-based products can build a higher-value position where sustainability records and source traceability matter most. This creates distinct roles for the 2 supply pathways in the niacin and niacinamide industry, with conventional production serving established bulk requirements and newer methods addressing customers that place greater value on process attributes.
Complete Report Scope:
- By Product Type
- Niacin
- Niacinamide
- By Source
- Synthetic
- Natural and Bio-Based
- By Form
- Powder
- Granular
- Liquid
- By Application
- Pharmaceuticals
- Human Nutrition
- Animal Nutrition
- Food and Beverages
- Cosmetics and Personal Care
- By Distribution Channel
- Direct Sales and Contract Supply
- Distributors and Wholesalers
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Retail and E-Commerce
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
Asia-Pacific accounted for 42.41% of the niacin and niacinamide market share in 2025. China’s large pyridine-based manufacturing base supports this position. Domestic demand also comes from functional foods, feed premixes, and personal care products. India adds pharmaceutical API and nutraceutical manufacturing capacity that strengthens the niacin and niacinamide market in Asia-Pacific. Jubilant Ingrevia commissioned a 5,000-metric-ton cGMP niacinamide facility in Bharuch, Gujarat, in January 2025 for food, nutrition, and cosmetics applications. The facility has USFDA approval and targets export-grade demand in the United States, Europe, and Japan, demonstrating a focus on customers that require globally recognized quality standards rather than only local bulk supply. Japan and South Korea also absorb high-purity niacinamide for premium skincare, where brands commonly emphasize product performance, established cosmetic quality practices, and ingredients that can be used in carefully positioned formulations. Their established cosmetics frameworks support product qualification and regular sourcing, which helps brands maintain product continuity when they introduce niacinamide across several premium skincare formats.North America is forecast to grow at 7.25% CAGR through 2031, the fastest regional rate. Demand is supported by premium supplements, science-based skincare products, and procurement diversification away from concentrated East Asian supply. FDA Human Foods Program priorities for 2026 emphasize ingredient documentation and supplier compliance. This setting favors suppliers able to provide complete audit records. Canada amended food additive and composition rules in December 2024, strengthening consistency across the regional regulatory environment. These requirements can raise the value of multi-region certification portfolios, because suppliers with complete technical files may be easier for buyers to qualify than vendors that require additional evidence or testing before a material can be approved for routine use. The niacin and niacinamide market size in North America is therefore supported by quality requirements as well as consumer demand.
Europe remains mature, but its demand is shifting toward verified quality and lower-carbon supply. Regulation (EC) No. 1925/2006 governs vitamin and mineral additions to foods and sets niacinamide limits for breakfast cereals. REACH and sustainability procurement expectations encourage bio-based sourcing in the niacin and niacinamide market among food, cosmetics, and consumer goods producers. Middle East and Africa gains from mandatory food fortification efforts in Nigeria and coordinated ECOWAS activity. These programs can create more regular demand through processed food channels as enforcement improves. Brazil supports South American demand through flour fortification and a growing dietary supplement base, providing an established base for suppliers serving both nutrition policy needs and consumer-led wellness demand. Argentina and other South American countries offer additional demand as urbanization and functional food adoption advance, although the core demand base continues to come from fortified foods and growing interest in dietary supplements.
List of Companies Covered in this Report:
- Anhui Redpont Biotechnology Co., Ltd.
- BASF
- Brother Enterprises Holding Co., Ltd.
- dsm-firmenich AG
- Evonik Industries
- Foodchem International
- Hubei Guangji Pharmaceutical Co., Ltd.
- Jubilant Pharmova Limited
- Kyowa Hakko Bio Co., Ltd.
- Lasons India Pvt. Ltd.
- Lonza Group
- Merck
- Shandong Hongda Biotechnology Co., Ltd.
- Tianjin Zhongrui Pharmaceutical Co., Ltd.
- Vanetta Food Ingredients
- Vertellus Holdings
- Zhejiang Lanbo Biotechnology Co., Ltd.
- Zhejiang NHU
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Anhui Redpont Biotechnology Co., Ltd.
- BASF SE
- Brother Enterprises Holding Co., Ltd.
- dsm-firmenich AG
- Evonik Industries AG
- Foodchem International Corporation
- Hubei Guangji Pharmaceutical Co., Ltd.
- Jubilant Pharmova Limited
- Kyowa Hakko Bio Co., Ltd.
- Lasons India Pvt. Ltd.
- Lonza Group AG
- Merck KGaA
- Shandong Hongda Biotechnology Co., Ltd.
- Tianjin Zhongrui Pharmaceutical Co., Ltd.
- Vanetta Food Ingredients
- Vertellus Holdings LLC
- Zhejiang Lanbo Biotechnology Co., Ltd.
- Zhejiang NHU Co., Ltd.

